One of the ways to look at asset utilization of Kiora is to check how much profit was generated for every dollar of assets it reports. Kiora Pharmaceuticals secures a negative usage of assets of -39.64 %, losing $0.4 for each dollar of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of Kiora Pharmaceuticals shows how discouraging it operates for each dollar spent on its assets.
The successful prediction of Kiora Pharmaceuticals
stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published
stock prices of traded companies, such as Kiora Pharmaceuticals, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at
the intrinsic value of Kiora Pharmaceuticals based on Kiora Pharmaceuticals hews, social hype, general headline patterns, and widely used
predictive technical indicators. We also calculate exposure to Kiora Pharmaceuticals's
market risk, different
technical and
fundamental indicators, relevant financial multiples and ratios, and then
comparing them to Kiora Pharmaceuticals's related companies.
Watch out for price decline
Please consider monitoring Kiora Pharmaceuticals on a daily basis if you are holding a position in it. Kiora Pharmaceuticals is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as Kiora Pharmaceuticals stock to be traded above the $1 level to remain listed. If Kiora Pharmaceuticals stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
Use Technical Analysis to project Kiora expected Price
Kiora Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Kiora Pharmaceuticals technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Kiora Pharmaceuticals trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions.
More Info...Kiora Pharmaceuticals Gross Profit
Kiora Pharmaceuticals Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Kiora Pharmaceuticals previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Kiora Pharmaceuticals Gross Profit growth over the last 10 years. Please check Kiora Pharmaceuticals'
gross profit and other
fundamental indicators for more details.
A Deeper Perspective
The big decline in price over the last few months for Kiora Pharmaceuticalsmay raise some interest from investors. The stock closed today at a share price of
0.41 on very low momentum in trading volume. The company directors and management failed to add value to investors and position the firm supply of money to exploit
market volatility in
May. However, diversifying your holdings with Kiora Pharmaceuticals or similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 7.73. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Kiora Pharmaceuticals partners.
Deferred Revenue Breakdown
Kiora Pharmaceuticals Deferred Revenue yearly trend continues to be fairly stable with very little volatility. Deferred Revenue is likely to outpace its year average in 2022. Deferred Revenue usually refers to a component of Total Liabilities representing the carrying amount of consideration received or receivable on potential earnings that were not recognized as revenue; including sales; license fees; and royalties; but excluding interest income. Kiora Pharmaceuticals Deferred Revenue is fairly stable at the moment as compared to the past year. Kiora Pharmaceuticals reported Deferred Revenue of 3.09 Million in 2021
| 2010 | 1.91 Million |
| 2016 | 4.22 Million |
| 2017 | 12.31 Million |
| 2018 | 2.69 Million |
| 2021 | 3.09 Million |
| 2022 | 4.68 Million |
Our take on Kiora Pharmaceuticals small slide
Current market risk adjusted performance is at -0.27. Kiora Pharmaceuticals is displaying above-average volatility over the selected time horizon. Investors should scrutinize Kiora Pharmaceuticals independently to ensure intended market timing strategies are aligned with expectations about Kiora Pharmaceuticals volatility. Kiora Pharmaceuticals is a potential penny stock. Although Kiora Pharmaceuticals may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Kiora Pharmaceuticals. We encourage investors to look for the signals such us email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Kiora instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of an artificial hype usually unable to maintain its increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.
Our Conclusion on Kiora Pharmaceuticals
While some firms in the biotechnology industry are either recovering or due for a correction, Kiora may not be as strong as the others in terms of longer-term growth potentials. With a somewhat neutral outlook on your 90 days horizon, it may be better to hold off any trading activity and neither trade new shares of Kiora nor trade your existing holdings in the Stock. It seems the expected volatility has not yet been fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Kiora Pharmaceuticals.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Gabriel Shpitalnik is a Member of Macroaxis Editorial Board. Gabriel is a young entrepreneur and writes predominantly on the business, technology, and finance sector. He likes to analyze different equity instruments across a wide range of industries focusing primarily on consumer products and evolving technologies.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of Kiora Pharmaceuticals. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
